Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
10.1016/j.cell.2017.07.008 · doi-reference
Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment
10.1016/j.chom.2013.07.007 · doi-reference
Gut Microbiota, Inflammation, and Colorectal Cancer
10.1146/annurev-micro-102215-095513 · doi-reference
Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer
10.1371/journal.pone.0039743 · doi-reference
The gut microbiota, bacterial metabolites and colorectal cancer
10.1038/nrmicro3344 · doi-reference
Lipid Metabolism in Biliary Tract Cancer: A New Therapeutic Target?
10.1245/s10434-022-11383-w · doi-reference
Asparagine Metabolism in Tumors Is Linked to Poor Survival in Females with Colorectal Cancer: A Cohort Study
10.3390/metabo12020164 · doi-reference
Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma?
10.1007/s12032-021-01468-z · doi-reference
Exome-wide somatic mutation characterization of small bowel adenocarcinoma
10.1371/journal.pgen.1007200 · doi-reference
ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma
10.1016/j.ejca.2014.04.007 · doi-reference
Small Bowel Adenocarcinoma: Etiology, Presentation, and Molecular Alterations
10.6004/jnccn.2019.7344 · doi-reference
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study
10.1158/1078-0432.ccr-22-0121 · doi-reference
Tumor mutational burden as a potential predictive marker for the efficacy of immunotherapy in advanced gastric cancer
10.1200/jco.2023.41.4_suppl.324 · doi-reference
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials
10.1001/jamaoncol.2021.0275 · doi-reference
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
10.1038/s41586-022-04508-4 · doi-reference
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
10.1001/jamaoncol.2020.3370 · doi-reference
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology
10.5858/arpa.2016-0331-cp · doi-reference
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
10.1016/s0140-6736(10)61121-x · doi-reference
Clinical significance of four molecular subtypes of gastric cancer identified by The Cancer Genome Atlas project
10.1158/1078-0432.ccr-16-2211 · doi-reference
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
10.1038/nm.3850 · doi-reference
Comprehensive molecular characterization of gastric adenocarcinoma
10.1038/nature13480 · doi-reference
The 2019 WHO classification of tumours of the digestive system
10.1111/his.13975 · doi-reference
Advances in targeted therapy for esophageal cancer
10.1038/s41392-020-00323-3 · doi-reference
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
10.1056/nejmoa2032125 · doi-reference
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
10.1016/s0140-6736(21)00797-2 · doi-reference
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
10.1016/s0140-6736(21)01234-4 · doi-reference
High SMAD4 levels appear in microsatellite instability and hypermethylated colon cancers, and indicate a better prognosis
10.1002/ijc.26473 · doi-reference
Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis
10.1038/nm.2457 · doi-reference
High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer
10.1080/2162402x.2017.1390640 · doi-reference
Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification
10.1136/jmedgenet-2011-100714 · doi-reference
A large multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancers with microsatellite instability
10.1200/jco.2017.35.15_suppl.3536 · doi-reference
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer
10.1200/jco.2009.27.1825 · doi-reference
Impact of MLH1, PMS2, MSH2, and MSH6 alterations on tumor mutation burden (TMB) and PD-L1 expression in 1,057 microsatellite instability-high (MSI-H) tumors
10.1200/jco.2018.36.15_suppl.3572 · doi-reference
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
10.1200/jco.2017.72.7107 · doi-reference
Aspirin exerts high anti-cancer activity in PIK3CA-mutant colon cancer cells
10.18632/oncotarget.20972 · doi-reference
Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances
10.3748/wjg.v22.i5.1745 · doi-reference
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
10.1093/annonc/mdy100 · doi-reference
Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Results of the randomized phase II PRODIGE 28-time UNICANCER study
10.1200/jco.2021.39.3_suppl.15 · doi-reference
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
10.1200/jco.20.02088 · doi-reference
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis
10.1016/j.ejca.2015.01.054 · doi-reference
